Boardroom Alpha
Start trial
10-K primary document
QTRX · Annual Report (Form 10-K) · Filed March 2, 2026

Quanterix Corp — 10-K exhibit

ex232-auditorconsentqtrxx2.htm
Quanterix Corp on Boardroom Alpha
Document
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statement (Form S-8 No. 333-223771) pertaining to the 2007 Stock Option and Grant Plan, as amended, the 2017 Employee Stock Purchase Plan, and 2017 Employee, Director, and Consultant Equity Incentive Plan,

(2) Registration Statement (Form S-8 No. 333-231373) pertaining to the 2017 Employee Stock Purchase Plan, and 2017 Employee, Director and Consultant Equity Incentive Plan,

(3) Registration Statement (Form S-8 No. 333-240420) pertaining to the 2017 Employee Stock Purchase Plan, and 2017 Employee, Director and Consultant Equity Incentive Plan,

(4) Registration Statement (Form S-8 No. 333-256032) pertaining to the 2017 Employee Stock Purchase Plan, and 2017 Employee, Director and Consultant Equity Incentive Plan,

(5) Registration Statement (Form S-8 No. 333-264836) pertaining to the 2017 Employee Stock Purchase Plan, and 2017 Employee, Director and Consultant Equity Incentive Plan,

(6) Registration Statement (Form S-8 No. 333-270295) pertaining to the 2017 Employee Stock Purchase Plan, and 2017 Employee, Director and Consultant Equity Incentive Plan,

(7) Registration Statement (Form S-8 No. 333-277643) pertaining to the 2017 Employee Stock Purchase Plan, and 2017 Employee, Director and Consultant Equity Incentive Plan,

(8) Registration Statement (Form S-8 No. 333-285924) pertaining to the 2017 Employee Stock Purchase Plan, and
2017 Employee, Director and Consultant Equity Incentive Plan,

(9) Registration Statement (Form S-8 No. 333-288648) pertaining to the Akoya Biosciences, Inc. 2021 Equity Incentive Plan, and Quanterix Corporation Restricted Stock Unit Inducement Awards,

(10) Post-effective Amendment No. 3 on Form S-8 to Form S-4 Registration Statement (Form S-8 POS No. 333-284932) pertaining to the Akoya Biosciences, Inc. 2021 Equity Incentive Plan, and Akoya Biosciences, Inc. 2015 Equity Incentive Plan,

(11) Registration Statement (Form S-8 No. 333-292362) pertaining to the 2025 Inducement Plan, and

(12) Registration Statement (Form S-8 No. 333-292759) pertaining to the Amended and Restated 2025 Inducement Plan;

of our report dated March 17, 2025, with respect to the consolidated financial statements of Quanterix Corporation included in this Annual Report (Form 10-K) of Quanterix Corporation for the year ended December 31, 2024.



/s/ Ernst & Young LLP

Boston, Massachusetts
March 2, 2026

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer